Stealth BioTherapeutics is a commercial stage biotech company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Forzinity (elamipretide) recently (9/2025) received FDA accelerated approval to improve muscle strength in children and adults weighing at least 30 kg with Barth syndrome, an ultra-rare mitochondrial disease. As we launch this first ever approved mitochondrial targeted therapeutic, we are also in late stage development for dry age-related macular degeneration and primary mitochondrial myopathy. We have a deep pipeline of mitochondrial targeted therapeutics in early development for rare genetic mitochondrial diseases and diseases of aging.